Research Chemical vs Prescription Peptides: What's Different

The same peptide name can describe very different products. A pen from a pharmacy, a vial from a compounding pharmacy, and a vial labeled "for research use only" may all say semaglutide, but they were made under different rules, checked in different ways, and overseen by different people, or by no one. This guide explains those differences in general terms, what independent testing of unregulated products has found, and what a certificate of analysis can and cannot tell you.

Three categories

A 2026 review of peptides in sports medicine describes the split well: many peptide drugs have gone through a rigorous approval process that evaluates both safety and efficacy, while a parallel "gray market" of unapproved compounds operates largely outside regulatory oversight (Mendias 2026). Using the US framework as a general example, products fall into three groups.

1. Approved drugs

An approved drug has been through the full sequence of clinical trial phases for a specific use, and the finished product is made under GMP (Good Manufacturing Practice). GMP is a set of enforceable manufacturing rules covering validated processes, batch records, quality testing, and sterile production for injectables.

2. Compounded medications

A compounding pharmacy prepares medications itself rather than dispensing a manufacturer's finished product. In the US there are two tiers:

• 503A pharmacies compound for individual patients with prescriptions. Pharmacy compounding has traditionally been regulated by state boards of pharmacy rather than the FDA (Qureshi 2014).
• 503B outsourcing facilities can compound larger batches without patient-specific prescriptions (Gianturco 2021). They are held to stricter FDA oversight and must comply with current good manufacturing practices, cGMP (Asbill 2026).

The 503B tier grew out of a disaster. In 2012–2013, contaminated injectable methylprednisolone from a compounding pharmacy caused fungal infections in 751 patients and 64 deaths, and the Drug Quality and Security Act followed in 2013 (Qureshi 2014).

Oversight is still imperfect. A study of 48 outsourcing facilities registered between 2020 and April 2025 found that only 11 had been inspected, on average 2.2 years after registration, and every inspected facility had at least two significant objectionable findings. Recurring problems included inadequate sterility testing and poor environmental controls (McCall 2026).

3. Research-use-only chemicals

A research chemical is sold for laboratory use and labeled not for human consumption. No approval is involved, no GMP requirement applies to the finished vial, and no regulator checks identity, dose, sterility or endotoxin before it ships. Whatever quality exists depends entirely on the seller.

What "quality" actually means

Four separate questions determine whether an injectable peptide is what it claims to be and safe to handle:

1. Identity. Is the molecule in the vial the one on the label?
2. Purity and content. How much of the labeled peptide is there, and what else is present (related impurities, truncated sequences, leftover synthesis reagents)?
3. Sterility. Are there living bacteria or fungi?
4. Endotoxin. Are there fragments of bacterial cell walls? These can be present even when no live bacteria remain, as the first study below shows.

A product can pass one of these and fail another, which is exactly what independent testing has found.

What testing of unregulated products has found

These studies bought or seized products and analyzed them in laboratories. Sample sizes are small, so treat them as documented examples rather than market-wide rates.

• Semaglutide from illegal online pharmacies. Researchers placed test orders with six sites. Three vials arrived; none of three ordered pens was delivered. The vials held 28.56–38.69% more semaglutide than labeled, had measured purity of only 7.7–14.37% against 99% claimed on the labels, and contained no viable microorganisms, yet endotoxin was detected in every sample, at 2.1645–8.9511 EU/mg (Ashraf 2024).
• Melanotan II from three online shops. Each shop claimed 10 mg per vial; the vials contained 4.32–8.84 mg. Vials from two shops had unknown impurities of 4.1–5.9% (Breindahl 2015).
• Look-alike molecules. Anti-doping laboratories analyzing black-market products identified glycine-extended versions of GHRP-6, GHRP-2 and ipamorelin, not the standard molecules, along with a growth hormone carrying an extra amino acid (Krug 2018). Another confiscated product contained a modified GHRH analog with incomplete C-terminal amidation, which the authors took as a sign of poor pharmaceutical quality (Esposito 2014).
• Nootropic peptides. A Belgian medicines lab identified Semax and Selank in unknown seized preparations and noted these peptides were freely available online as injectable powders and nasal sprays (Vanhee 2020).
• Performance products more broadly. Of 75 pharmaceuticals seized from the black market among bodybuilders in France (mostly steroids rather than peptides), 33% were substandard, 32% counterfeit, and 19% matched their label (Fabresse 2021).

The semaglutide study makes the key point: a product can be free of live microbes and still carry endotoxin, and a label can promise 99% purity that the contents do not deliver.

What a COA can and cannot tell you

A certificate of analysis (COA) is a report of tests run on a sample. Two methods appear on most peptide COAs:

• HPLC separates the components of a sample and reports what share of the detected signal comes from the main peak. It speaks to purity.
• Mass spectrometry measures molecular mass. It speaks to identity: does the main compound weigh what the labeled peptide should?

The melanotan II study shows how the two work together: liquid chromatography with UV detection quantified the peptide and its impurities, while tandem mass spectrometry confirmed identity (Breindahl 2015).

A COA can tell you what a lab found in the sample it tested, if the lab is real and the report is genuine.

A COA cannot tell you:

• that your vial came from the batch that was tested;
• anything about sterility or endotoxin, unless those tests are specifically listed with results;
• how many milligrams are in the vial, unless it reports a quantitative content (assay) result, which is different from percent purity;
• that the document itself is authentic.

Our article on gray-market COA red flags walks through how to spot a COA that should not be trusted.

At a glance

Evidence about a peptide's effects comes from studies that used a known, characterized product. Those results say nothing about whether a particular vial matches that product. Our methodology page explains how we label research status and disclose affiliate relationships.

Sources

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 2026. PMID 41966639
• Sterile compounding: clinical, legal, and regulatory implications for patient safety. J Manag Care Spec Pharm, 2014. PMID 25443512
• Outsourcing facilities and their place in the U.S. drug supply chain. J Am Pharm Assoc (2003), 2021. PMID 32863181
• Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities. Int J Pharm Compd, 2026. PMID 42143782
• A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities. J Am Pharm Assoc (2003), 2026. PMID 42242462
• Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res, 2024. PMID 39509151
• Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal, 2015. PMID 24771717
• Analysis of new growth promoting black market products. Growth Horm IGF Res, 2018. PMID 29864719
• Identification of the growth hormone-releasing hormone analogue [Pro1, Val14]-hGHRH with an incomplete C-term amidation in a confiscated product. Drug Test Anal, 2014. PMID 25283153
• The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal, 2020. PMID 31667971
• Analysis of pharmaceutical products and dietary supplements seized from the black market among bodybuilders. Forensic Sci Int, 2021. PMID 33838562

This article is for educational and research purposes only and is not medical advice.